BON Bon Natural Life Ltd Annual reports only
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1816815 · Fiscal year ends 09/30
Financial factors as of 2025-09-30 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-21.7%
TTM net income YoY-601.0%
TTM EPS YoY-117.4%
Revenue 3-yr CAGR-14.5%
Net income 3-yr CAGR—
Margins
Gross margin20.8%
Operating margin-8.7%
Net margin-10.7%
FCF margin0.7%
EBITDA margin-2.9%
Returns
ROE-3.9%
ROA-2.7%
ROIC (approx.)-2.6%
Asset turnover0.25x
Leverage & solvency
Liabilities / assets31.9%
Debt / equity0.03x
Current ratio1.74x
Interest coverage-4.43x
Cash quality & payout
Operating cash flow / net income-0.07x
Accruals ratio-2.9%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 |
|---|---|---|
| Income statement | ||
| Revenue | $18.67M | $23.84M |
| Cost of revenue | $14.79M | $16.73M |
| Gross profit | $3.88M | $7.11M |
| R&D expense | $754,193 | $1.62M |
| SG&A expense | $4.31M | $3.35M |
| Operating income | -$1.62M | $1.87M |
| Interest expense | $366,180 | $303,325 |
| Pretax income | -$1.71M | $715,939 |
| Income tax | $339,414 | $351,179 |
| Net income | -$1.99M | $398,172 |
| EBITDA | -$535,580 | $2.98M |
| EPS (basic) | -0.72 | 4.17 |
| EPS (diluted) | -0.72 | 4.14 |
| Weighted avg. shares (diluted) | 2.76M | 96,114 |
| Balance sheet | ||
| Cash & equivalents | $6.27M | $658,610 |
| Receivables | $11.01M | $11.78M |
| Inventory | $3.31M | $1.57M |
| Current assets | $45.76M | $39.79M |
| PP&E, net | $18.16M | $15.01M |
| Intangibles | $6.42M | $776,995 |
| Total assets | $85.19M | $61.77M |
| Current liabilities | $26.31M | $16.45M |
| Short-term debt | $1.08M | $461,765 |
| Long-term debt | $842,815 | $970,061 |
| Total debt | $1.92M | $1.43M |
| Total liabilities | $27.19M | $17.42M |
| Shareholders' equity | $57.55M | $43.91M |
| Net debt | -$4.34M | $773,216 |
| Shares outstanding | — | 3.97M |
| Cash flow statement | ||
| Operating cash flow | $141,115 | -$7.72M |
| Capital expenditure | $6,827 | $7,047 |
| Free cash flow | $134,288 | -$7.73M |
| Investing cash flow | -$10.00M | -$15,727 |
| Financing cash flow | $15.45M | $8.76M |
| Depreciation & amortization | $1.09M | $1.11M |
| Stock-based compensation | $1.39M | $1.32M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.